Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Tom DuBois who wrote (5299)	9/14/1998 12:43:00 PM
From: margie	Read Replies (1) \| Respond to of 6136

Thank you. I still think your "I have a dream" post was great. However Michael Waldholtz from the WSJ is about to talk about some new AIDS drug on CNBC (I don't know which) and you know what happens to the stock price when someone mentions a "NEW DRUG" even if it is not even in clinical trials, or is complementary, or is not in the same class, or is years away from marketing. It is a shame that some investors lack confidence in the company, mainly because they do not have sufficient information, and every time another drug is mentioned, there is an overreaction. Jesse Eisinger must be reading SI for him to comment that investors "have not been overly impressed with the quality of the company'science." He must be referring to a few vocal posters who seem to know so little about scientific method in general that they keep asking for information about the status of BLINDED clinical trials in progress. They just have this "anxious" feeling that since there is no news, it must be bad. They feel Agouron "owes" them this information. They don't realize that Agouron does not know either, as the trials are blinded, and are being carried out at approved sites, headed by independent investigators, and if Agouron did try to find out at this point, they would be sanctioned by the FDA. But thestreet couldn't pass up a chance to knock Agouron.